Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a publicly traded company. The agreement comes after years of financial ...

Shares of bluebird bio (NASDAQ:BLUE) continued their downward descent Monday in the wake of news that the company has agreed to be taken private by Carlyle Group (NASDAQ:CG) and SK Capital ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the ...

Bluebird’s lead CAR-T cancer cell therapy idecabtagene vicleucel (ide-cel) was last year hit with an FDA refuse-to-file letter, which required additional data on chemistry, manufacturing and ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million. Bluebird on ...

bluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions ...

Bluebird bio to be acquired by Carlyle Group & SK Capital, offering up to $9.84/share based on product performance. Former Mirati CEO David Meek set to lead bluebird post-acquisition, with deal ...

bluebird bio (NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private ...

For a full version of this story, visit STAT. Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $ ...